QTEX · QTREX Quantum Ltd. · Insider Trading

The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: (i) 33.34% of the RSUs will vest on the first anniversary date following July 1, 2026 (the "First Instalment"); and (ii) 8.33% of the RSUs will vest on a quarterly basis over 8 quarters (two (2) years), following the First Instalment. The grant of RSUs was approved by the Company's shareholders at an Extraordinary General Meeting of Shareholders held on August 28, 2026.

The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: (i) 33.34% of the RSUs will vest on the first anniversary date following July 1, 2026 (the "First Instalment"); and (ii) 8.33% of the RSUs will vest on a quarterly basis over 8 quarters (two (2) years), following the First Instalment. The grant of RSUs was approved by the Company's shareholders at an Extraordinary General Meeting of Shareholders held on August 28, 2026.

The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: (i) 33.34% of the RSUs will vest on the first anniversary date following July 1, 2026 (the "First Instalment"); and (ii) 8.33% of the RSUs will vest on a quarterly basis over 8 quarters (two (2) years), following the First Instalment. The grant of RSUs was approved by the Company's shareholders at an Extraordinary General Meeting of Shareholders held on August 28, 2026.

The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: (i) 33.34% of the RSUs will vest on the first anniversary date following July 1, 2026 (the "First Instalment"); and (ii) 8.33% of the RSUs will vest on a quarterly basis over 8 quarters (two (2) years), following the First Instalment. The grant of RSUs was approved by the Company's shareholders at an Extraordinary General Meeting of Shareholders held on August 28, 2026.

The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: 183,334 RSUs will vest on July 1, 2027, and the remaining RSUs will vest on a quarterly basis over two years following the first vesting event.

The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: 183,334 RSUs will vest on October 1, 2026, and the remaining RSUs will vest on a quarterly basis over two years following the first vesting event.

The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: 183,334 RSUs will vest on July 1, 2027, and the remaining RSUs will vest on a quarterly basis over two years following the first vesting event.

The Restricted Share Units ("RSUs") were granted under Qtrex Quantum Ltd.'s (formerly Insense Medical) 2019 Plan, and will vest according to the following schedule: 183,334 RSUs will vest on July 1, 2027, and the remaining RSUs will vest on a quarterly basis over two years following the first vesting event.

Following the vesting of the Restricted Share Units ("RSUs") granted under Qtrex Quantum Ltd.'s Insense Medical 2019 Plan, with each RSU representing the right to receive, following vesting, one ordinary share, no par valuer per share (the "Ordinary Shares"), the underlying Ordinary Shares received were then sold. The securities were sold by the Reporting Person pursuant to an existing 10b5-1 plan.

Following the vesting of the Restricted Share Units ("RSUs") granted under Qtrex Quantum Ltd.'s Insense Medical 2019 Plan, with each RSU representing the right to receive, following vesting, one ordinary share, no par valuer per share (the "Ordinary Shares"), the underlying Ordinary Shares received were then sold.

The options were granted with an exercise price of NIS 0.37.

The options were granted on November 1, 2020 and are fully vested as of June 1, 2022.

The options were granted with an exercise price of AUD 0.37.

The options were granted on February 15, 2020 and became fully vested as of June 2, 2019.

Following the vesting of the Restricted Share Units ("RSUs") granted under Qtrex Quantum Ltd.'s Insense Medical 2019 Plan, with each RSU representing the right to receive, following vesting, one ordinary share, no par valuer per share (the "Ordinary Shares"), the underlying Ordinary Shares received were then sold. The securities were sold by the Reporting Person pursuant to an existing 10b5-1 plan.

The securities were sold by the Reporting Person pursuant to an existing 10b5-1 plan.

The securities were sold by the Reporting Person pursuant to an existing 10b5-1 plan.

The securities were sold by the Reporting Person pursuant to an existing 10b5-1 plan.

The options were granted on February 21, 2021 and became fully vested as of February 23, 2024.

The securities were sold by the Reporting Person pursuant to an existing 10b5-1 plan.

The securities were sold by the Reporting Person pursuant to an existing 10b5-1 plan.

The securities were sold by the Reporting Person pursuant to an existing 10b5-1 plan.